openPR Logo
Press release

Autoimmune Hepatitis Treatment Market Size is expected to increase by 2034, estimates DelveInsight

09-18-2024 05:06 PM CET | Health & Medicine

Press release from: ABNewswire

Autoimmune Hepatitis Treatment Market Size is expected

Autoimmune Hepatitis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Autoimmune Hepatitis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight's "Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Autoimmune Hepatitis, historical and forecasted epidemiology as well as the Autoimmune Hepatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock detailed insights into the Autoimmune Hepatitis Market by downloading the comprehensive report from DelveInsight @ Autoimmune Hepatitis Therapeutics Market [https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Autoimmune Hepatitis Market Report

* In August 2024:- Novartis Pharmaceuticals- Patients will be randomly assigned to different doses of VAY736 or placebo. The primary analysis is planned at 24 weeks. A subsequent study part will then test the efficacy and safety of VAY736 in a parallel group design. For this part of the trial a new group of autoimmune hepatitis patients will be enrolled.
* In August 2024:- Kezar Life Sciences, Inc.- This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allows patients to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.
* According to the American Liver Foundation, Autoimmune Hepatitis (AIH) is a disease in which the body's immune system attacks the liver and causes it to become inflamed. The disease is chronic, meaning it lasts many years. If untreated, it can lead to cirrhosis and liver failure.
* It was found that the prevalence of AIH in the US is approximately 31.2 per 100,000 individuals.
* The leading Autoimmune Hepatitis Companies such as Abbott Laboratories, AbbVie, Inc., Arihantanam Life Care Pvt Ltd., AstraZeneca PLC, Bayer AG, Biocon, Ltd., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Co., Cipla, Ltd., GlaxoSmithKline PLC, Gilead Life sciences, Inc., Johnson & Johnson Services, Inc., Inova Diagnostics, Inc., Merck & Co., Inc., Novartis International AG, Organovo Holdings, Inc., Pfizer, Inc., Upcyte Technologies GmbH, and others.
* Promising Autoimmune Hepatitis Therapies such as VAY736, HR19042 Capsules, zetomipzomib, and others.

Gain a competitive edge in the Autoimmune Hepatitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Autoimmune Hepatitis Treatment Drugs [https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Autoimmune Hepatitis Epidemiology Segmentation in the 7MM

* Total Autoimmune Hepatitis Prevalent Cases
* Autoimmune Hepatitis Gender-specific Diagnosed Prevalent Cases
* Autoimmune Hepatitis Type-specific Diagnosed Prevalent Cases
* Total Autoimmune Hepatitis Diagnosed Prevalent Cases
* Autoimmune Hepatitis Age-specific Diagnosed Prevalent Cases
* Autoimmune Hepatitis Treated Cases

Autoimmune Hepatitis Market Insights

The goal of treatment of AIH is to stop the body's attack on itself by suppressing the immune system. The basic treatment is the administration of immunosuppressive drugs, the first of which is the oral drug corticosteroid. Medications help to regulate an overactive immune system. Both type 1 and type 2 autoimmune hepatitis are commonly treated with daily doses of the steroid prednisone. Initially, a high dose may be prescribed, which will be gradually reduced as the disease is controlled. The aim is to determine the lowest effective dose that manages the condition.

Discover key developments and opportunities in the Autoimmune Hepatitis Market. Click here to learn more from DelveInsight's latest report @ Autoimmune Hepatitis Market Size [https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Autoimmune Hepatitis Treatment Market Landscape

The Autoimmune Hepatitis treatment market is shifting towards personalized and precision medicine. Efforts are focused on understanding the underlying disease mechanisms to tailor therapies more effectively to individual patients. This includes exploring genetic and molecular profiles to guide treatment decisions and improve outcomes. The emphasis is increasingly on integrating innovative research findings to address the limitations of current treatments and enhance patient care.

Autoimmune Hepatitis Emerging Drugs Profile

* Zetomipzomib (KZR-616): Kezar Life Sciences
* Ianalumab (VAY736): Novartis/MorphoSys

Download DelveInsight's Autoimmune Hepatitis Market report today and stay ahead in this rapidly evolving field. @ Autoimmune Hepatitis Clinical Trials [https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Autoimmune Hepatitis Market Report

* Coverage- 7MM
* Autoimmune Hepatitis Companies- Abbott Laboratories, AbbVie, Inc., Arihantanam Life Care Pvt Ltd., AstraZeneca PLC, Bayer AG, Biocon, Ltd., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Co., Cipla, Ltd., GlaxoSmithKline PLC, Gilead Life sciences, Inc., Johnson & Johnson Services, Inc., Inova Diagnostics, Inc., Merck & Co., Inc., Novartis International AG, Organovo Holdings, Inc., Pfizer, Inc., Upcyte Technologies GmbH, and others.
* Autoimmune Hepatitis Therapies- VAY736, HR19042 Capsules, zetomipzomib, and others.
* Autoimmune Hepatitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Autoimmune Hepatitis Unmet Needs, KOL's views, Analyst's views, Autoimmune Hepatitis Market Access and Reimbursement

Download the report to understand which factors are driving Autoimmune Hepatitis Market Trends @ Autoimmune Hepatitis Market Trends [https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Executive Summary of Autoimmune Hepatitis

3. Competitive Intelligence Analysis for Autoimmune Hepatitis

4. Autoimmune Hepatitis: Market Overview at a Glance

5. Autoimmune Hepatitis: Disease Background and Overview

6. Patient Journey

7. Autoimmune Hepatitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Autoimmune Hepatitis Unmet Needs

10. Key Endpoints of Autoimmune Hepatitis Treatment

11. Autoimmune Hepatitis Marketed Products

12. Autoimmune Hepatitis Emerging Therapies

13. Autoimmune Hepatitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Autoimmune Hepatitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=autoimmune-hepatitis-treatment-market-size-is-expected-to-increase-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Autoimmune Hepatitis Treatment Market Size is expected to increase by 2034, estimates DelveInsight here

News-ID: 3659750 • Views:

More Releases from ABNewswire

Needle Holder Market: USD 367.3M in 2024 to USD 530.3M by 2029, CAGR 7.6%
Needle Holder Market: USD 367.3M in 2024 to USD 530.3M by 2029, CAGR 7.6%
Browse 280 market data Tables and 40 Figures spread through 250 Pages and in-depth TOC on "Needle Holder Market by Type (Mayo-Hegar, Olsen-Hegar, Crilewood, Derf, Castroviejo), Application (Surgery, Microsurgery, Dental), Material (Stainless Steel, Tungsten Carbide), Usage Type (Reusable, Single Use), End User, Region - Global Forecast to 2029 The global needle holder market [https://www.marketsandmarkets.com/Market-Reports/needle-holder-market-260494054.html?utm_source=abnewswire.com&utm_medium=needleholdermarket] is forecasted to grow from USD 367.3 million in 2024 to USD 530.3 million by 2029, reflecting
Asthma Treatment Market Size in the 7MM was ~USD 19,000 million in 2023, estimated DelveInsight
Asthma Treatment Market Size in the 7MM was ~USD 19,000 million in 2023, estimat …
Asthma Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Asthma Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence. DelveInsight's "Asthma Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as
Cardiac Tissue Engineering Market to Reach USD 1,333.6 M by 2029, Driven by Stem Cell Research and Support
Cardiac Tissue Engineering Market to Reach USD 1,333.6 M by 2029, Driven by Stem …
Browse 426 market data Tables and 54 Figures spread through 336 Pages and in-depth TOC on "Cardiac Tissue Engineering Market by Material (Scaffold, Stem cells), Product (Heart Valve, Vascular Grafts), Applications (MI,Congenital Heart Disease), End-User (Hospitals & Clinics, Academics & Research Institutes) - Global Forecast to 2029 The cardiac tissue engineering market [https://www.marketsandmarkets.com/Market-Reports/cardiac-tissue-engineering-market-264276500.html?utm_source=abnewswire.com&utm_medium=cardiactissueengineeringmarket] is expected to grow from USD 621.2 million in 2024 to USD 1,333.6 million by 2029, reflecting a
Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024
Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insights, Treatment Drugs, Clinica …
DelveInsight's, "Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and

All 5 Releases


More Releases for Autoimmune

Autoimmune Disease Diagnostics Market - Forecast to 2026
The findings reviewed by GME stated that the Global Autoimmune Disease Diagnostics Market would grow at a CAGR value of 8.9 percent from 2021 to 2026. Today, the advancing technology & automation, increasing awareness about risks and implications of autoimmune disease if left undiagnosed & untreated, and the awareness about the benefits of various diagnostics available are accelerating growth in the market. Also, there has been an exponential increase
The Autoimmune Registry releases first complete list of autoimmune diseases with …
The Autoimmune Registry Inc (ARI) has published its first comprehensive List of Autoimmune Diseases: https://www.autoimmuneregistry.org/autoimmune-diseases. It includes over 150 diseases, 40 subtypes, and 60 synonyms. ARI created the list to provide patients and researchers easy access to the latest literature and information about autoimmune disease. ARI’s list is searchable and filterable, with links to peer-reviewed research, patient groups, and other resources. Between 15 and 30 million people in
Autoimmune Disease Diagnostics Market: Growing Awareness among People about Auto …
According to the recent report by Transparency Market Research, the global autoimmune disease diagnostics market has a highly consolidated scenario. The market is dominated by a handful of players. However, these players have a stronghold over the dynamics of market and pose a great challenge for any new entrant to set its foot in the market. Read Report Overview - https://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html To reduce effects of such hindrances, the new entrants are
Autoimmune Disease Therapeutics Market Boost due to increase in incidence of aut …
According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is expected to reach $153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025. Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/5185?utm_source=openpr&utm_medium=Niranjan Autoimmune disease therapeutics include
Autoimmune Treatment Market North America Leads the Global Autoimmune Treatment …
The global autoimmune treatment market is growing significantly due to increasing incidences of autoimmune diseases, up surging healthcare expenditure, and advancements in the technologies for the development of autoimmune diseases therapeutics. Autoimmune diseases are chronic in nature and do not have permanent treatment. This creates ample growth opportunity for the autoimmune treatment market, to grow at a considerable rate in the coming years. The advanced research and development facilities, and
Autoimmune Disease Diagnostics Market: Rise in Autoimmune Diseases, alongside Gr …
Global Autoimmune Disease Diagnostics Market: Snapshot The global autoimmune disease diagnostics market is expected to witness a modest growth in the coming years on account of the growing incidences of autoimmune diseases among people worldwide. Efficient autoimmune disease diagnostics has become absolutely essential to tackle this issue. Governments across nations are also increasing their spending towards healthcare in light of these growing incidences of autoimmune diseases. This has also resulted in